Shilpa Medicare Ltd's Q3FY25 Quarter Results
- 11 Feb 2025
Result Summary
- Shilpa Medicare Ltd reported a 8.1% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 11.0%.
- Its expenses for the quarter were down by 10.4% QoQ and up 2.1% YoY.
- The net profit increased 77.0% QoQ and increased 593.9% YoY.
- The earnings per share (EPS) of Shilpa Medicare Ltd stood at 3.3 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 320.45 | 348.79 | 288.70 | -8.1% | 11.0% |
Total Expenses | 279.18 | 311.62 | 273.47 | -10.4% | 2.1% |
Profit Before Tax | 41.27 | 37.16 | 15.23 | 11.1% | 171.0% |
Tax | 9.83 | 18.83 | 9.46 | -47.8% | 3.9% |
Profit After Tax | 31.78 | 17.95 | 4.58 | 77.0% | 593.9% |
Earnings Per Share | 3.30 | 1.80 | 0.50 | 83.3% | 560.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Shilpa Medicare Ltd is a pharmaceutical company primarily engaged in the manufacturing and sale of pharmaceuticals, specializing in oncology and other therapeutic areas. The company operates within the healthcare sector, focusing on the development and production of active pharmaceutical ingredients (APIs) and finished dosage forms. Shilpa Medicare has established a presence in both domestic and international markets, catering to the needs of the pharmaceutical industry. The company is known for its strong emphasis on research and development, aiming to bring innovative healthcare solutions to the market. Recent developments in the company have not been specified in the data provided.
Revenue
During the third quarter of the fiscal year 2025 (Q3FY25), Shilpa Medicare Ltd reported a total income of ₹320.45 crores. This represents a decrease of 8.1% compared to the second quarter of fiscal year 2025 (Q2FY25), where the total income was ₹348.79 crores. However, when compared to the third quarter of the previous fiscal year (Q3FY24), the total income increased by 11.0% from ₹288.70 crores. These figures indicate fluctuations in the company's revenue streams over the past year, with a notable year-over-year growth.
Profitability
The profitability metrics for Shilpa Medicare Ltd in Q3FY25 show significant improvement compared to previous periods. The company achieved a profit before tax of ₹41.27 crores, marking an increase of 11.1% from ₹37.16 crores in Q2FY25 and a substantial rise of 171.0% from ₹15.23 crores in Q3FY24. The tax expense for Q3FY25 was ₹9.83 crores, showing a significant reduction of 47.8% compared to the previous quarter. Consequently, the profit after tax surged to ₹31.78 crores, exhibiting a remarkable quarter-over-quarter increase of 77.0% and a year-over-year growth of 593.9% from ₹4.58 crores in Q3FY24. Earnings per share (EPS) also advanced to ₹3.30, reflecting a growth of 83.3% from Q2FY25 and a substantial increase of 560.0% from Q3FY24.
Operating Metrics
The total expenses for Shilpa Medicare Ltd in Q3FY25 were reported at ₹279.18 crores, which is a reduction of 10.4% compared to ₹311.62 crores in Q2FY25. On a year-over-year basis, the total expenses increased slightly by 2.1% from ₹273.47 crores in Q3FY24. This indicates a control over costs in the most recent quarter. The company has managed to enhance its profitability despite the reduction in total income, as evidenced by the significant improvements in profit before tax and profit after tax. Additionally, the decrease in tax expenses has positively impacted the company's bottom line, contributing to the overall improved financial performance.
